Clonal Cytopenia of Undetermined Significance
3
Pipeline Programs
3
Companies
3
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
2100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
2028
2029
2030
Bristol Myers SquibbEnasidenib
ServierIvosidenib
Astex PharmaceuticalsInqovi
Clinical Trials (3)
Total enrollment: 143 patients across 3 trials
Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial
Start: Oct 2024Est. completion: Feb 202915 patients
Phase 2Recruiting
Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
Start: Apr 2022Est. completion: Jan 203020 patients
Phase 2Active Not Recruiting
Early Intervention in High Risk CCUS
Start: Feb 2025Est. completion: Dec 2028108 patients
Phase 1Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 143 patients
Small Molecule is the dominant modality (100% of programs)
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.